Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 27 February 2025

 
 
 
   

Policy changes required to prevent deaths from noncommunicable diseases and strengthen Europe’s economy

 
Learn more here

A new report - developed by R-Health Consult and commissioned for EFPIA - provides an analysis of the economic and health benefits of investment in five key non-communicable diseases (NCDs).

The research looks at stroke, ischaemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease (COPD), and breast cancer across the 27 European Union Member States and makes recommendations on how to reduce mortality, improve quality of life for patients while improving return on investments (ROI) for the European economy. 

It shows that substantial ROI can be made from targeted health interventions; it uses specific insights from case studies in three countries - Portugal, Romania, and Sweden.  

Read more


 
 
 
   

Blogs

 

How the CARE Consortium took on COVID-19 and what comes next
27 February 2025

CARE Consortium published its white paper, telling the story of its five year journey from a flying start in April 2020... Read more

 
 
 
   

Events

 

Cancer Care 2030: From policy ambition to impact
19 March 2025 (Brussels, Belgium)

Join us on 19 March in Brussels to discuss how we can work together to accelerate progress to improve cancer care Read more

Unlocking efficiency through reliance: Navigating the EMA post-authorization framework
03 April 2025 (Virtual event)

Register now to join this webinar. Read more

 
 
 
   

2024 Pipeline: Gene therapies

Gene therapies offer patients living with rare diseases like Duchenne Muscular Dystrophy the hope of relief from pain - and maybe even a cure.

Imagine how many lives could be changed. 

Discover more in our pipeline review.

 
 
 
 
   

What we are reading

 
New Belgian government aims to strengthen clinical trial competitiveness
On 24 February 2025 (Euractiv)

Belgium plans to reinforce its global competitiveness in clinical research as the new government sets an ambitious... Read more

Clinical Evidence 2030
On 14 February 2025 (ASCPT)

Excellence of clinical evidence is the heart of every well-informed decision on the development, authorization, reimbursement,... Read more